# InMode InMode is an Asset Manager based in Yokneam Illit, Israel. ## Overview - **Organization type:** Asset Manager - **Headquarters:** Yokneam Illit, Israel - **Region:** Middle East - **Address:** Yokneam Illit, Israel - **Founded:** 2008 - **Assets under management:** Undisclosed - **Website:** inmodemd.com ## Regulatory record - **Reports private funds:** No ## About InMode was founded in 2008 by Moshe Mizrahy and Michael Kreindel, who previously co-founded Syneron Medical. The company emerged from a deep engineering background in radio-frequency and light-based energy technologies. Its initial product platform, BodyTite, applied RFAL (Radio-Frequency Assisted Lipolysis) — an internally developed technique for fat removal and skin contraction — that quickly gained adoption among plastic surgeons and dermatologists. By 2019, InMode listed on Nasdaq under ticker INMD, raising roughly $70 million in an IPO led by Barclays, UBS, and Canaccord Genuity. InMode's strategy rests on a proprietary bipolar radio-frequency platform that powers a growing suite of minimally invasive and non-invasive aesthetic treatments. The portfolio spans three categories: minimally invasive (FaceTite, AccuTite, BodyTite, Morpheus8), non-invasive (Triton, Evolve), and a women's health line (EmbraceRF). Unlike competitors that outsource manufacturing, InMode owns its production lines in Israel, which sustains gross margins above 80%. Its direct-sales model bypasses traditional distributor layers, placing trained representatives in key markets including the United States, Canada, India, and Western Europe — a structure that keeps pricing power and clinical training tightly controlled. The firm's deployment has remained heavily weighted toward organic product development and geographic expansion rather than acquisition. InMode reported $492 million in revenue for the full year 2023, with GAAP net income of $198 million — a 40% net margin that reflects its manufacturing leverage. In April 2024, the company launched the IgniteRF system, which targets full-body skin revitalization using fractional RF, in select North American markets before a planned broader rollout later that year. While its balance sheet holds over $700 million in cash and equivalents, share buybacks have been the primary capital-allocation tool; the board authorized a $100 million repurchase program in early 2024. What separates InMode structurally from MedTech peers is its founder-led R&D engine. Both Mizrahy and Kreindel remain active in product design, generating a pipeline that has historically required no external acquisitions to refresh. The company's Israeli headquarters houses all core intellectual property, while its North American subsidiaries in Toronto and Irvine run commercial operations. This dual geography — R&D in Israel, sales management in North America — creates an operational moat around rapid clinical iteration. The firm's governance, however, is unorthodox: Mizrahy holds a Class B share structure that gives him controlling voting power, a feature that has drawn proxy advisory scrutiny but remains intact as of June 2024. ## Sectors - Medical Devices & Aesthetics ## Offices - Toronto, Canada - Irvine, CA, United States ## People - Moshe Mizrahy — Chairman and CEO - Michael Kreindel — Co-founder and CTO ## Questions ### Who runs product development and clinical strategy at InMode? Co-founder and CTO Michael Kreindel leads the technology roadmap, drawing on decades of physics and engineering expertise in RF and laser-based energy systems. Both Kreindel and CEO Moshe Mizrahy remain actively involved in product design, a continuity that dates back to their prior venture, Syneron Medical. The clinical advisory function is supported by InMode's network of practicing surgeons and dermatologists who provide feedback on procedural protocols and device ergonomics. ### What is InMode's relationship with its legacy competitor, Syneron Medical? Co-founders Moshe Mizrahy and Michael Kreindel previously built Syneron Medical, a pioneer in combined optical and RF aesthetic devices that went public on Nasdaq in 2004 and later merged with Candela. InMode's genesis in 2008 reflected a deliberate departure toward RFAL (Radio-Frequency Assisted Lipolysis) — a technology the founders felt was underserved by Syneron's product line. There is no ongoing corporate relationship between the entities. ### Which geographic markets drive InMode's revenue? The United States accounts for the majority of InMode's sales, reflecting the country's high concentration of plastic surgeons, dermatologists, and medical spas. Canada, India, and Western European markets form the next tier. The company reports segment revenue across the Americas, EMEA, and Asia-Pacific, with direct-sales operations in each region supported by local training centers and clinical specialists. ### Does InMode make acquisitions or return capital to shareholders? InMode has historically avoided acquisitions, preferring to develop devices internally through its R&D team in Israel. With over $700 million in cash and equivalents reported as of early 2024, the company has expanded its capital-return program; the board authorized a $100 million share repurchase program in February 2024. Dividends have not been part of the capital-allocation policy to date. ### How does InMode's intellectual-property strategy differ from competitors? InMode owns its full manufacturing process in Yokneam Illit, Israel, and retains in-house the core patents covering bipolar RF delivery, temperature monitoring, and specific handpiece designs. The majority of competitors in the aesthetic-device space contract manufacturing to third parties or license key technologies from university labs. InMode's IP posture allows it to launch iterative upgrades — such as the Morpheus8 Burst handpiece — on shorter timelines than typical MedTech cycles. ## Related profiles - [Theravance Biopharma](https://altss.com/profile/theravance-biopharma-inc) - [Power Solutions International](https://altss.com/profile/power-solutions-international-inc) --- Last updated: 2026-06-03T20:00:00.000Z Canonical page: https://altss.com/profile/inmode-ltd Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology